title: Accelerated fracture healing with teriparatide.
abstract: Satisfactory healing of the osteoporotic fracture is critically important to functional recovery, morbidity, and quality of life. Some therapies for osteoporosis may affect the processes associated with bone repair. For example, bisphosphonates in experimental models are associated with increased callus size and mineralization, reduced callus remodeling, and improved mechanical strength. Local and systemic bisphosphonate treatment may improve implant fixation. No negative impact on fracture healing has been observed, even after major surgery or when administered immediately after fracture. For the osteoanabolic agent teriparatide, case reports and a randomized trial have produced mixed results, but they are consistent with a positive impact of teriparatide on fracture healing. Some of the agents currently being developed for osteoporosis, notably sclerostin and DKK1 antibodies have shown a beneficial effect on fracture healing. At this point, therefore, there is no evidence that osteoporosis therapies are detrimental to fracture healing with some promising experimental evidence for positive effects on healing, notably for those agents whose actions are primarily anabolic.
authors.affiliation: Universidade Católica de Brasília, Brasília, DF, Brazil. jlborges@metabolismo.com.br
authors.forename: João Lindolfo C
authors.initials: JL
authors.lastname: Borges
authors.forename: Anderson
authors.initials: A
authors.lastname: Freitas
authors.forename: John P
authors.initials: JP
authors.lastname: Bilezikian
mesh_terms: D000369:Aged, 80 and over; D015519:Bone Density; D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D005260:Female; D005265:Femoral Neck Fractures / Q000188:drug therapy*; D017102:Fracture Healing / Q000187:drug effects*; D006801:Humans; D058866:Osteoporotic Fractures / Q000188:drug therapy*; D016032:Randomized Controlled Trials as Topic; D019379:Teriparatide / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D050071:Bone Density Conservation Agents; D019379:Teriparatide